source
- Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insuranceWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 4d ago↗ source
- FDA approves prostate cancer and Crohn’s disease therapies as judge rejects effort to block Lilly weight‑loss adsThe U.S. Food and Drug Administration announced approvals for new treatments targeting prostate cancer and Crohn’s disease. The decisions expand therapeutic options for patients with these conditio…